Actively Recruiting
Study to Assess Safety, Pharmacokinetics, and Pharmacodynamics of NS-079 Compared to Placebo in Healthy Adults
Led by NeuShen Therapeutics · Updated on 2026-09-15
78
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are studying the safety, pharmacokinetics, and pharmacodynamics of NS-079 and its main metabolite NS-079-M1 in healthy adults aged 18 to 55. The trial aims to determine if NS-079 is safe and tolerable under the tested dosing regimen and to understand how the body processes NS-079, including the effect of paroxetine. This Phase I, double-blind, placebo-controlled trial compares NS-079 to a placebo to evaluate safety and tolerability. Participants receive different doses of NS-079 or placebo in single ascending dose SAD and multiple ascending dose MAD groups. The study also includes a drug-drug interaction DDI part to assess the effect of paroxetine when given with NS-079. The dosing periods vary by group, with SAD evaluated over 4 days, MAD over 14 days, and DDI over 30 days. During the study, participants undergo medical assessments including physical exams, vital signs, ECGs, and lab tests. Blood or saliva samples are collected for genetic testing. Researchers closely monitor treatment-related adverse events and measure pharmacokinetic parameters through blood and urine samples at specified intervals. The total study duration includes dosing and safety follow-up periods up to 30 days.
CONDITIONS
Brief Title
A Phase I Study of NS-079 in Healthy Participants
Research Team
J
Jin Lili, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here